Among different types of breast cancers (BC), triple-negative BC (TNBC) amounts to 15% to
20% of breast malignancies. Three principal characteristics of TNBC cells are (i) extreme …

Neuroendocrine prostate cancer is a histological variant of prostate cancer that is
characterized by aggressiveness, poor clinical outcomes, and expression of neuroendocrine …

Castration-resistant prostate cancer (CRPC) is the most aggressive, incurable form of
prostate cancer. MDV3100 (enzalutamide), an antagonist of the androgen receptor (AR) …

Purpose: Enzalutamide, a second-generation antiandrogen, was recently approved for the
treatment of castration-resistant prostate cancer (CRPC) in patients who no longer respond …

Although the newly developed second-generation anti-androgen drug enzalutamide can
repress prostate cancer progression significantly, it only extends the survival of prostate …

Oxidative stress, inflammation and androgen receptor (AR) signaling play a pivotal role in
the initiation, development and progression of prostate cancer (PCa). Numerous papers in …

Although early detection and treatment of prostate cancer (PCa) improves outcomes, many
patients still die of metastatic PCa. Here, we report that metastatic PCa exhibits reduced …

Genetic aberrations of the androgen receptor (AR) caused by mutations, rearrangements,
and polymorphisms result in a mutant receptor that has varied functions compared to wild …

Rationale: The progression of prostate cancer (PCa) to castration-resistant PCa (CRPC)
despite continuous androgen deprivation therapy is a major clinical challenge. Over 90% of …

Androgen receptor (AR) is closely associated with a group of hormone‐related diseases
including the cancers of prostate, breast, ovary, pancreas, etc and anabolic deficiencies …